pharma · Knee Osteoarthritis · Hypoplastic Left Heart Syndrome · RGBP
Regeneron Ireland Designated
Regeneron Ireland Designated Activity Company (DAC)
Regeneron Ireland Designated clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- LA MESA, CA, IE
- Programs
- 10
- Drugs
- 62
- Patents
- 8292
Regeneron Ireland Designated projects
5 ClinicalTrials.gov programs sponsored by Regeneron Ireland Designated.
Regeneron Ireland Designated has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Autologous Bone Marrow-derived Mononuclear Cells
Regeneron Ireland Designated Activity Company (DAC)
Congenital Heart Disease
1 trial -
Autologous mononuclear cells
Regeneron Ireland Designated Activity Company (DAC)
Congenital Heart Disease, SRV Dependent
1 trial -
Extracellular Vesicles from Mesenchymal Stem Cells
Regeneron Ireland Designated Activity Company (DAC)
COVID-19 Pneumonia
1 trial -
MSC-derived exosomes
Regeneron Ireland Designated Activity Company (DAC)
Long COVID-19 Syndrome
1 trial -
autologous cell-based delivery
Regeneron Ireland Designated Activity Company (DAC)
Hypoplastic Left Heart Syndrome
1 trial
Frequently asked questions
How many clinical projects does Regeneron Ireland Designated have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.